[Progress in therapy of erectile dysfunction. New orally administered drugs].
Lenk
S
S
Klinik und Poliklinik für Urologie, Universitätsklinikum Charité der Humboldt-Universität zu Berlin.
D000284:Administration, Oral; D001058:Apomorphine / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D010646:Phentolamine / Q000009:adverse effects / Q000627:therapeutic use*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D014196:Trazodone / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015016:Yohimbine / Q000009:adverse effects / Q000627:therapeutic use
D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D015016:Yohimbine; D000068677:Sildenafil Citrate; D001058:Apomorphine; D014196:Trazodone; D010646:Phentolamine